
ESM Table 2: Distribution of donors and assays performed

	Pan	creas	Spleen	Duodenum	PLN
Donor Group	VP1 IHC	HLA Class I	VP1 IHC	VP1 IHC	VP1 IHC
No Diabetes	76	54	37	21	0
Single AAb positive (AAb+)	19	20	9	9	0
Dual Aab positive (AAb++)	9	9	4	4	1
Type 1 diabetes Residual ICIs	40	39	16	10	4
Type 1 diabetes IDIs only	42	27	30	26	5
TOTAL	186	149	96	70	10


ESM Table 3: Distribution of donors and assays performed

Donor Group	Spleen		Duo	denum	PLN	
	Total (n)	No. VP1+ (%)	Total (n)	No. VP1+ (%)	Total (n)	No. VP1+ (%)
No Diabetes	37	9 (24.3%)	21	3 (14.3%)	0	-
Single AAb positive (AAb+)	9	3 (33.3%)	9	4 (44.4%)	0	-
Dual Aab positive (AAb++)	4	1 (25%)	4	1 (25%)	1	1 (100%)
Type 1 diabetes Residual ICIs	16	8 (50.0%)	10	3 (30%)	4	2 (50%)
Type 1 diabetes IDIs only	30	13 (43.3%)	26	12 (46.2%)	5	3 (60.0%)
All T1D	46	21 (45.7%)	36	15 (41.7%)	9	5 (55.5%)
AAb+, AAb++ and T1D	59	25 (42.4%)	49	20 (40.8%)	1	1 (100%)
TOTAL	96	34 (35.4%)	71	23 (32.4%)	10	6 (60%)

a.




b.



**ESM Figure 1a: Enteroviral VP1 immunostaining in a virally-infected cell microarray**. Representative immunostaining of VP1 in uninfected control cells (negative control), and cells infected with CVB1, CVB3, CVB4, echovirus 6 (Echo6) and enterovirus 71 (E71). Positive staining was observed in CVB1, 3, 4 and echo6, while no staining was seen in uninfected control cells or E71.

**ESM Figure 1b: Enteroviral VP1 immunostaining in normal tissue microarray.** Nerve, renal glomeruli, appendix, endometrium, duodenum, liver, adrenal cortex, testis and renal tubules were all negative for VP1. Scale bars - 100μm.

### **ESM Figure 2**



**ESM Figure 2a.** Representative images of VP1+ cells in nPOD donor pancreas, spleen, duodenum and PLN, compared with VP1- donors.


**ESM Figure 2b.** The proportion of donors in each donor group that have VP1 immunopositivity in both the spleen and pancreas.

**ESM Figure 2c.** The proportion of donors in each donor group that have VP1 immunopositivity in both the duodenum and pancreas.

**ESM Figure 2d.** The proportion of donors in each donor group that have VP1 immunopositivity in 0, 1, 2, or 3 different organs (pancreas, spleen and duodenum).

Two sided Fishers Exact Test with significance shown after FDR corrections for multiple comparisons.

### **ESM Figure 3**



**ESM Figure 3a.** Representative images of two islets with normal HLA-I expression, one containing a VP1+ cell and one VP1-.

ESM Figure 3b. Representative images of two islets with normal HLA-I expression, both VP1-.

**ESM Figure 3c.** Representative images of one islet with elevated HLA-I expression containing a VP1+ cell.

ESM Figure 3d. Representative images of one islet with elevated HLA-I expression and VP1-.

**ESM Figure 3e.** Representative images of two islets with HLA-I hyperexpression, one containing several VP1+ cells and one VP1-.

**ESM Figure 3f.** Representative images of two islets with HLA-I hyperexpression, one containing several VP1+ cells and one VP1-.

## nPOD-Virus group members:

## nPOD-V Funding 2012: Funding Reference Breakthrough T1D (former JDRF) JDRF-25-2012-516

#### **Participants:**

- Pugliese, Alberto, M.D. Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.
- Atkinson, Mark, Ph.D. University of Florida, USA.
- Campbell-Thompson, Martha University of Florida, USA.
- Chapman, Nora, Ph.D. University of Nebraska, USA.
- Coppieters, Ken University of Ghent, Belgium.
- Dotta, Francesco, M.D. University of Siena, Italy.
- Eisenbarth, George, M.D., Ph.D. Barbara Davis Center for Childhood Diabetes, USA.
- Ferreira, Ricardo, Ph.D JDRF/WT Diabetes & Inflammation Laboratory, USA.
- Frisk, Gun, Ph.D. University of Uppsala, Sweden.
- Gianani, Roberto, M.D. Barbara Davis Center for Childhood Diabetes, USA.
- Gerling, Ivan, Ph.D University of Tennessee, USA.
- Homann, Dirk, M.D. University of Colorado at Denver, USA.
- Hyöty, Heikki, Ph.D. Tampere University, Finland.
- Lloyd, Richard, Ph.D. Baylor College of Medicine, USA.
- Kaddis, John, Ph.D. City of Hope National Medical Center, USA.
- Kent, Sally, Ph.D. University of Massachusetts, USA.
- Morgan, Noel, Ph.D. University of Exeter, UK.
- Nadler, Jerry, M.D., Ph.D. East Virginia Medical School, USA.
- Morris Fear, Margareta, Ph.D. East Virginia Medical School, USA.
- Nyalwhide, Julius, Ph.D. East Virginia Medical School, USA.
- Oikarinen, Maarit Tampere University, Finland.
- Plagnol, Vincent, Ph.D. University College of London, UK.
- Petrosino, Joseph, Ph.D. Baylor College of Medicine, USA.
- Richardson, Sarah, Ph.D. University of Exeter, UK.
- Sarkar, Suparna Barbara Davis Center for Childhood Diabetes, USA.
- Schneider, Darius La Jolla Institute for Allergy & Immunology, USA.
- Thackray, Larissa, Ph.D. Washington University, USA.
- Toniolo, Antonio. M.D. University of Insubria, Italy.
- Virgin, Herbert Washington University, USA.
- Von Herrath, Matthias La Jolla Institute for Allergy & Immunology, USA.

## nPOD-V Grant 2017: Funding Reference Breakthrough T1D (former JDRF) JDRF-3-SRA-2017-492-A-N

#### Participants:

 Alberto Pugliese, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope, Duarte, CA, USA.

- Richard Lloyd, Baylor College of Medicine, USA.
- Margaret Morris, Eastern Virginia Medical School, USA.
- Roberto Mallone, INSERM, Paris, France.
- Malin Flodström Tullberg, Karolinska Institutet, Sweden.
- Matthias von Herrath, La Jolla Institute for Allergy and Immunology, USA.
- Jerry Nadler, Eastern Virginia Medical School, USA.
- Julius Nyalwidhe, Eastern Virginia Medical School, USA.
- Teresa Rodriguez-Calvo, La Jolla Institute for Allergy & Immunology, USA and Helmholtz Munich, Germany.
- Sally Kent, University of Massachusetts Medical School, USA.
- Antonio Toniolo, University of Insubria, Italy.
- Kathrin Maedler, University of Bremen, Germany.
- Marc Horwitz, University of British Columbia, Canada.
- Noel Morgan, University of Exeter Medical School, UK.
- Sarah Richardson, University of Exeter Medical School, UK.
- Mark Atkinson, University of Florida, USA.
- Ivan Gerling, The University of Tennessee Health Science Center, USA.
- Heikki Hyöty, Tampere University, Finland.
- Isaac Snowhite, University of Miami School of Medicine, USA.
- Filippo Canducci, University of Insubria, Italy.
- Alessandro Salvatoni, University of Insubria, Italy.

# Additional members (some participated in discussions, but their participation in the group was more informal).

- Soile Tuomela PhD (Karolinska Institutet, Sweden)
- Ben Giepmans PhD (University of Groningen, Netherlands)
- Varpu Marjomaki PhD (University of Jyväskylä, Finland)